1. Home
  2. SONM vs DRMA Comparison

SONM vs DRMA Comparison

Compare SONM & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SONM

Sonim Technologies Inc.

HOLD

Current Price

$3.15

Market Cap

6.2M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONM
DRMA
Founded
1999
2014
Country
United States
United States
Employees
N/A
9
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SONM
DRMA
Price
$3.15
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
30.5K
82.0K
Earning Date
04-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.01
N/A
Revenue
$58,298,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
$0.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$1.10
52 Week High
$12.30
$7.33

Technical Indicators

Market Signals
Indicator
SONM
DRMA
Relative Strength Index (RSI) 35.53 49.85
Support Level $2.66 $1.13
Resistance Level $4.41 $1.40
Average True Range (ATR) 0.40 0.10
MACD -0.10 -0.01
Stochastic Oscillator 16.56 28.12

Price Performance

Historical Comparison
SONM
DRMA

About SONM Sonim Technologies Inc.

DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: